Publication details
VII. národní den klinických hodnocení
| Title in English | VII. National Clinical Trials Day |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Conference |
| MU Faculty or unit | |
| Citation | |
| Description | This year's National Clinical Trials Day, organized by the Large Research Infrastructure CZECRIN in Prague, traditionally focused on the topic of clinical trials, which are focused on evaluating the safety and efficacy of new drugs or treatments. The conference was supported by the Ministry of Health, which is aware of the need for support in this area and thus the benefit for patients. One of the main topics of the conference was the position of clinical trials in the Czech Republic in the European field. They play a crucial role in the development of innovative drugs and have a direct impact on the quality of life of patients. Clinical trials have been conducted in the Czech Republic for more than three decades. Currently, more than 480 are underway in many healthcare facilities and more than 16 thousand patients are involved in them, which puts us in a strong position in European comparison. The key to maintaining such a position and its further development is the support of clinical trials, including ensuring a sufficient number of qualified study coordinators. The initiative of the Ministry of Health of the Czech Republic to harmonize the environment for conducting clinical trials was presented at the conference by the Chief Director of the Ministry of Health for Legislation and Law, JUDr. Radek Policar: "We plan to create a national strategy for the Czech Republic to improve the environment for conducting clinical drug trials. Thanks to clinical drug trials that take place in hospitals and outpatient clinics, our patients have access to the most modern treatment. Support for this activity is therefore support for the benefit of patients and research teams, and at the same time saves costs for the public health insurance system, because the drugs are paid for by those who initiate the research, and they also pay those who participate in the research." The view of the national regulatory authority was also added by the Director of the Department of Clinical Drug Evaluation of the SÚKL, MUDr. Alice Němcová. The moderated discussions discussed the possibilities of strengthening the position of the Czech Republic on the map of clinical research (not only) by connecting with European initiatives, which also included improving clinical practice or financing medical research in cooperation with foreign guests. |
| Related projects: |